Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Stock Has Consensus Target Price of $16.00 According to Brokerages

by · The Cerbat Gem

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) has been assigned an average recommendation of “Hold” from the six analysts that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $16.00.

NTHI has been the subject of a number of research reports. Weiss Ratings lowered Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Wall Street Zen raised shares of Neonc Technologies from a “strong sell” rating to a “sell” rating in a report on Sunday, October 18th. Zacks Research cut shares of Neonc Technologies from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 7th. Roth Capital began coverage on Neonc Technologies in a research note on Thursday, September 24th. They issued a “buy” rating on the stock. Finally, BTIG Research restated a “buy” rating and issued a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, September 8th.

Read Our Latest Report on NTHI

Neonc Technologies Stock Performance

Shares of NASDAQ:NTHI opened at $3.26 on Thursday. Neonc Technologies has a twelve month low of $2.50 and a twelve month high of $12.00. The business has a fifty day moving average of $3.48 and a 200-day moving average of $5.52.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Insider Transactions at Neonc Technologies

In related news, CEO Thomas Chen purchased 12,757 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were purchased at an average price of $5.49 per share, with a total value of $70,035.93. Following the completion of the purchase, the chief executive officer owned 13,705 shares in the company, valued at $75,240.45. This represents a 1,345.68% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Amir Heshmatpour acquired 35,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were bought at an average price of $3.30 per share, for a total transaction of $115,500.00. Following the completion of the acquisition, the chief executive officer owned 3,183,000 shares of the company’s stock, valued at $10,503,900. This trade represents a 1.11% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 134,812 shares of company stock worth $530,149.

Hedge Funds Weigh In On Neonc Technologies

Large investors have recently bought and sold shares of the company. Bank of America Corp DE increased its position in Neonc Technologies by 5.0% during the first quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock worth $1,650,000 after buying an additional 11,108 shares during the last quarter. Westmount Partners LLC lifted its position in Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after acquiring an additional 153,858 shares during the last quarter. BlackRock Inc. bought a new position in shares of Neonc Technologies during the second quarter worth approximately $815,000. Finally, Global Retirement Partners LLC bought a new position in shares of Neonc Technologies during the second quarter worth approximately $126,000.

Neonc Technologies Company Profile

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

See Also